The Daily Fuckup

President Trump’s tariff program is looking less like a single trade policy than a stack of overlapping rules. For companies trying to price imports, place orders, or lock in supply contracts, the hard part is not just the headline rate. It is working through the exceptions, timing rules, partner-specific treatment, and product classifications that can change the final bill.

The White House’s April 2 action on patented pharmaceuticals is a clear example. The fact sheet says Trump imposed a 100% tariff on patented pharmaceutical products and ingredients, but it also says the tariffs do not hit every company the same way or all at once. For certain large firms, the tariffs take effect in 120 days; for smaller firms, in 180 days. Products from the European Union, Japan, Korea, Switzerland and Liechtenstein face a 15% tariff, while products from the United Kingdom get a lower rate under a separate agreement. Companies that sign both most-favored-nation pricing agreements with the Health and Human Services Department and onshoring agreements with the Commerce Department can get a 0% tariff through January 20, 2029. Firms that only take the onshoring route face a 20% tariff. Generic drugs and biosimilars are not covered at this time. In other words, the policy is real, but the operative rate depends on who is shipping, what they ship, and which paperwork they sign.

That same pattern shows up in the White House’s other tariff moves. The February 20 import-surcharge proclamation imposed a temporary 10% ad valorem duty for 150 days, effective February 24, 2026, while preserving the administration’s ability to stack it with existing restrictions. The result is a cumulative structure rather than a tidy one: an importer may have to account for the surcharge, then layer on a product-specific duty, then check whether any country deal, exemption, or timing rule changes the outcome.

The April 2 metals action adds another layer. The White House says articles made entirely or almost entirely of steel, aluminum, or copper will pay 50% on their full value; derivative articles substantially made of those metals will pay 25%; certain metal-intensive industrial and electrical-grid equipment will pay 15% through 2027; products made abroad but entirely with American steel, aluminum, and copper will be subject to 10%; and products with 15% or less metal content are no longer subject to Section 232 metals tariffs. That is not a simple tariff wall. It is a pricing system with multiple thresholds and narrow definitions that will matter a great deal to anyone trying to count costs before a shipment lands.

The political message is straightforward: tariffs are being sold as leverage, national security, and supply-chain discipline. The administrative reality is messier. The White House keeps using tariffs as a pressure tool, but the more it relies on product carve-outs, delayed start dates, and partner-specific rates, the harder it becomes for businesses to know what the policy actually costs them. Large firms can hire lawyers and compliance teams to map the rules. Smaller firms usually cannot. For them, uncertainty is not an abstract market condition; it is an operating expense.

That is the central problem with the current tariff design. The administration wants the public to see resolve. Businesses see an unfinished rulebook. Investors see a moving target. And because the official documents keep adding exceptions as fast as they add rates, the final price of Trump’s tariff regime is often visible only after a company has already made the wrong assumption.